ClinicalTrials.gg
CompletedNCT04386616COVASTILUpdated Jan 10, 2022Results posted

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

A Phase 2 interventional study of MSTT1041A and MSTT1041A-matched Placebo in COVID-19 Pneumonia, sponsored by Genentech, Inc.. Completed at 41 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
345th of 1,321
396 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
317th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 345th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 317th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.

03

Conditions studied

  • COVID-19 Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan
  • Peripheral capillary oxygen saturation (SpO2) ≤93% (on room air or supplemental oxygen) or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤300 millimetres of mercury (mmHg) or requiring supplemental oxygen to maintain SpO2 >93% or requirement for supplemental oxygen to maintain SpO2 at an acceptable level per local standard of care

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or positive pregnancy test at screening
  • Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
  • Participating in another clinical drug trial
  • Treatment with therapy (other than for COVID-19) within 5 half-lives or 30 days (whichever is longer) prior to initiation of study drug
  • Use of Janus kinase (JAK) inhibitor within 30 days or 5 drug elimination half-lives (whichever is longer) prior to screening
  • Have received high-dose systemic (≥1 mg/kg/day methylprednisolone or equivalent) within 72 hours prior to Day 1
  • Known infection with CD4 \<200 cells/microlitre (uL) or \<14% of all lymphocytes
  • or AST >10 times the (ULN) detected at screening
  • History of anaplastic large-cell lymphoma or mantle-cell lymphoma
  • History of cancer within the previous 5 years unless it has been adequately treated and considered cured or remission-free in the investigator's judgment
  • Clinical evidence of active or unstable cardiovascular disease (e.g., acute myocardial ischemia or decompensated heart failure), as determined by investigator assessment, , laboratory assessment, or echocardiographic data
  • History of moderate or severe allergic, anaphylactic, or anaphylactoid reactions or to any component of study treatment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
396 participants (actual)

Study arms

  • Placebo comparator
    All Placebo

    Participants randomized to this arm received one intravenous (IV) infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo on Day 1. A second IV infusion of either MSTT1041A-matched placebo or UTTR1147A-matched placebo (same placebo as the first infusion) was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.

    Drug: MSTT1041A-matched Placebo · Drug: UTTR1147A-matched Placebo

  • Experimental
    MSTT1041A

    Participants randomized to this arm received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.

    Drug: MSTT1041A

  • Experimental
    UTTR1147A

    Participants randomized to this arm received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen. Study treatment was given in combination with the standard of care for COVID-19 pneumonia.

    Drug: UTTR1147A

Interventions

  • Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.

    Also known as: Astegolimab, RG6149, RO7187807

  • DrugMSTT1041A-matched Placebo

    Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.

  • Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.

    Also known as: Efmarodocokin alfa, RG7880, RO7021610, IL-22Fc

  • DrugUTTR1147A-matched Placebo

    Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.

06

What researchers measure

Primary outcomes

  1. Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28

    The time to recovery was defined as the time from baseline to a clinical status score of 1 or 2 on the 7-category ordinal scale (whichever occurs first); clinical status scores are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death.

    Time frame: From Baseline up to 28 days

Secondary outcomes

  1. Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status by Day 28

    The 7 categories of the clinical status ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death

    Time frame: From Baseline up to 28 days

  2. Time to Hospital Discharge or "Ready for Discharge" by Day 28

    Hospital discharge is category number 1 out of the 7 categories of the clinical status ordinal scale, and it is defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen).

    Time frame: Up to 28 days

  3. Duration of Supplemental Oxygen by Day 28

    Duration of supplemental oxygen was defined as the number of days during the 28-day treatment period when the participant is alive and receives "Supplemental Oxygen or other forms of ventilation", as recorded in the Vital Signs and Oxygen Saturation form. For each participant, the duration of multiple non-consecutive periods during which the participant received supplemental oxygen was summed. For any days prior to Day 28 where status of supplemental oxygen use was missing, the last known status was to be carried forward.

    Time frame: Up to 28 days

  4. Percentage of Participants Alive and Free of Respiratory Failure by Day 28

    Respiratory failure was defined as requiring non-invasive ventilation, high-flow oxygen, mechanical ventilation, or extracorporeal membrane oxygenation \[ECMO\]).

    Time frame: Up to 28 days

  5. Clinical Status Score at Day 14, Assessed Using a 7-Category Ordinal Scale

    The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death

    Time frame: Day 14

  6. Clinical Status Score at Day 28, Assessed Using a 7-Category Ordinal Scale

    The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death

    Time frame: Day 28

  7. Percentage of Participants Needing Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Day 28

    Time frame: Up to 28 days

  8. Number of Ventilator-Free Days by Day 28

    The number of ventilator-free days was defined as the number of days during the 28-day treatment period when the participant is alive and without need for invasive mechanical ventilation. For any day during Day 1 and Day 28, if invasive mechanical ventilation or ECMO was recorded for any part of the day ( \>= 12 hours during mechanical invasive ventilation for patients with tracheostomy), the day was not to be counted as a ventilator-free day; otherwise, the day was to be counted. For any days prior to Day 28 where status of mechanical ventilator was missing, the last known status was to be carried forward. The total number of days was the sum of all ventilator-free days, regardless of whether the days occurred consecutively or in nonconsecutive intervals.

    Time frame: Up to 28 days

  9. Percentage of Participants With an Intensive Care Unit (ICU) Stay by Day 28

    Time frame: Up to 28 days

  10. Duration of Intensive Care Unit (ICU) Stay by Day 28

    Duration of ICU stay was calculated as the total number of hours (expressed in days) spent in ICU up to and inclusive of 28 days. ICU duration was derived from the ICU Stay Information Log using the difference between ICU discharge date/time and ICU admission date/time. If ICU admission occurred before randomization, the ICU duration was to be counted from the date of dosing. Partial admission and discharge date/time were to be imputed following a conservative approach. For each participant, durations of multiple ICU stays were to be summed.

    Time frame: Up to 28 days

  11. Time to Clinical Failure by Day 28, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)

    Time frame: Up to 28 days

  12. Percentage of Participants Who Died by Day 14

    Time frame: Up to Day 14

  13. Percentage of Participants Who Died by Day 28

    Time frame: Up to Day 28

  14. Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) Aggregate Score of ≤2 Maintained for 24 Hours

    The National Early Warning Score 2 (NEWS2) is a system for scoring the physiological measurements that are routinely recorded at the patient's bedside. Its purpose is to identify acutely ill patients. The NEWS2 scoring system measures 7 physiological parameters: respiration rate, peripheral capillary oxygen saturation, breathing air or supplementary oxygen, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, and body temperature. A score of 0, 1, 2, or 3 is allocated to each parameter (except for air or oxygen, with respective scores of 0 and 2); a higher score means the parameter is further from the normal range. The scores for each parameter are then summed (with an aggregate score ranging from 0 to 20), and a higher aggregate score indicates a worse clinical condition of the patient, thus indicating the need for a more urgent clinical response.

    Time frame: Up to 28 days

  15. Safety Summary of the Number of Participants With at Least One Adverse Event, With Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

    The terms "severe" and "serious" are not synonymous with respect to an adverse event (AE). Severity refers to the intensity of an AE (rated according to NCI-CTCAE v5.0 criteria or, if not listed, the following scale: Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard SAE criteria), such as a life-threatening or fatal AE or an AE that prolongs inpatient hospitalization. Severity and seriousness were independently assessed by the investigator for each AE that was recorded. The investigator also assessed each AE for whether the event was considered to be related to the study drug.

    Time frame: From Baseline until study completion/discontinuation (up to 60 days)

  16. Number of Participants With Clinical Laboratory Test Abnormalities by Highest NCI-CTCAE Grade Post-Baseline

    Clinical laboratory tests were performed over the course of the study and the grading of any abnormal values outside of the normal range (High or Low) was based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0); the higher the grade, the greater the lab parameter deviated from the normal range. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase; INR = international normalized ratio; aPTT = activated partial thromboplastin time

    Time frame: From Baseline up to 60 days

  17. Number of Participants With Vital Sign Abnormalities at Anytime Post-Baseline

    The number of participants with vital sign abnormalities outside of the normal upper (i.e., High) and lower limits (i.e., Low) were summarized for each parameter. The normal reference range used for each vital sign parameter was as follows: Diastolic Blood Pressure, 50-90 millimetres of mercury (mmHg); Oxygen Saturation, ≥94%; Pulse Rate, 60-100 beats per minute; Respiratory Rate, 8-20 breaths per minute; Systolic Blood Pressure, 90-140 mmHg; Temperature, 36.5-38 degrees Celsius (C). Not every vital sign abnormality qualified as an adverse event. A vital sign result was to be reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgement.

    Time frame: From Baseline up to 60 days

  18. Number of Participants by the Investigator's Interpretations of Electrocardiogram Recordings at Specified Timepoints

    Electrocardiogram (ECG) recordings were to be performed after the participant had been resting in a supine position for at least 10 minutes if possible. The investigator's interpretation of the ECG (e.g., normal or abnormal) was recorded.

    Time frame: Baseline, Days 14 and 28, Discharge Day (up to Day 28), and Study Completion Visit (up to Day 60)

  19. Percentage of Participants Who Tested Positive for Anti-Drug Antibodies (ADAs) to MSTT1041A and UTTR1147A at Baseline and at Anytime Post-Baseline

    Serum samples were collected, and participants who received treatment with MSTT1041A or MSTT1041A-matched placebo were assessed for antidrug antibodies (ADAs) to MSTT1041A, while those who received UTTR1147A or UTTR1147A-matched placebo were assessed for ADAs to UTTR1147A. Participants who received placebo treatment were only assessed for the presence of ADAs at baseline. The percentage of ADA-positive participants at baseline (baseline prevalence) and after drug administration (postbaseline incidence) are summarized. When determining postbaseline incidence, participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response).

    Time frame: At Baseline (pre-dose on Day 1) and post-baseline (Days 15 and 28; and discharge day and study completion [up to 60 days])

  20. Serum Concentration of UTTR1147A at Specified Timepoints

    Time frame: For the first dose: at 0.5 hours post-dose on Day 1, on Days 2, 3, 7, and 15; and for the second dose: Days 15 (0.5 hours post-dose), 21, and 28

  21. Serum Concentration of MSTT1041A at Specified Timepoints

    Time frame: For the first dose: at 0.5 hours post-dose on Day 1, on Days 2, 3, 7, and 15; and for the second dose: Days 15 (0.5 hours post-dose), 21, and 28

07

Results

Posted Jan 10, 2022

Participant flow

Participant flow — Overall Study
MilestoneAll PlaceboMSTT1041AUTTR1147A
Started134130132
Received at least one dose of study drug134130132
Completed both doses of study drug at day 15312725
Completed10495104
Not completed303528
Withdrew: Death222221
Withdrew: Lost to follow-up586
Withdrew: Withdrawal by subject241
Withdrew: Adverse event110

Outcome measures

PrimaryTime to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28

The time to recovery was defined as the time from baseline to a clinical status score of 1 or 2 on the 7-category ordinal scale (whichever occurs first); clinical status scores are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death.

Time frame:
From Baseline up to 28 days
Reported as:
Median · Days
Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28
DaysAll PlaceboMSTT1041AUTTR1147A
Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 2810.0 (8.0 to 14.0)11.0 (9.0 to 14.0)10.0 (8.0 to 13.0)
Statistical analysis
  • All Placebo vs MSTT1041A · Unstratified Log Rank · p = 0.9266 (p\<0.05 threshold for statistical significance) · Hazard ratio (hr): 1.01 · 95% CI 0.75 to 1.36The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Unstratified Log Rank · p = 0.3570 (p\<0.05 threshold for statistical significance) · Hazard ratio (hr): 1.15 · 95% CI 0.86 to 1.54The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Stratified Log Rank · p = 0.9812 (p\<0.05 threshold for statistical significance) · Hazard ratio (hr): 1.00 · 95% CI 0.74 to 1.36The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Stratified Log Rank · p = 0.5151 (p\<0.05 threshold for statistical significance) · Hazard ratio (hr): 1.10 · 95% CI 0.82 to 1.49The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryTime to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status by Day 28

The 7 categories of the clinical status ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death

Time frame:
From Baseline up to 28 days
Reported as:
Median · Days
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status by Day 28
DaysAll PlaceboMSTT1041AUTTR1147A
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status by Day 2810.0 (8.0 to 14.0)11.0 (9.0 to 13.0)10.0 (8.0 to 12.0)
Statistical analysis
  • All Placebo vs MSTT1041A · Unstratified Log Rank · p = 0.8373 · Hazard ratio (hr): 1.03 · 95% CI 0.77 to 1.39The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Unstratified Log Rank · p = 0.3396 · Hazard ratio (hr): 1.15 · 95% CI 0.86 to 1.55The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Stratified Log Rank · p = 0.8619 · Hazard ratio (hr): 1.03 · 95% CI 0.76 to 1.39The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Stratified Log Rank · p = 0.4913 · Hazard ratio (hr): 1.11 · 95% CI 0.82 to 1.50The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryTime to Hospital Discharge or "Ready for Discharge" by Day 28

Hospital discharge is category number 1 out of the 7 categories of the clinical status ordinal scale, and it is defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen).

Time frame:
Up to 28 days
Reported as:
Median · Days
Time to Hospital Discharge or "Ready for Discharge" by Day 28
DaysAll PlaceboMSTT1041AUTTR1147A
Time to Hospital Discharge or "Ready for Discharge" by Day 2810.0 (8.0 to 14.0)11.0 (9.0 to 13.0)10.0 (8.0 to 13.0)
Statistical analysis
  • All Placebo vs MSTT1041A · Unstratified Log Rank · p = 0.4711 · Hazard ratio (hr): 1.11 · 95% CI 0.83 to 1.49The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Unstratified Log Rank · p = 0.3135 · Hazard ratio (hr): 1.16 · 95% CI 0.87 to 1.56The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Stratified Log Rank · p = 0.5735 · Hazard ratio (hr): 1.09 · 95% CI 0.81 to 1.48The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Stratified Log Rank · p = 0.5973 · Hazard ratio (hr): 1.08 · 95% CI 0.80 to 1.46The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryDuration of Supplemental Oxygen by Day 28

Duration of supplemental oxygen was defined as the number of days during the 28-day treatment period when the participant is alive and receives "Supplemental Oxygen or other forms of ventilation", as recorded in the Vital Signs and Oxygen Saturation form. For each participant, the duration of multiple non-consecutive periods during which the participant received supplemental oxygen was summed. For any days prior to Day 28 where status of supplemental oxygen use was missing, the last known status was to be carried forward.

Time frame:
Up to 28 days
Reported as:
Median · Days
Duration of Supplemental Oxygen by Day 28
DaysAll PlaceboMSTT1041AUTTR1147A
Duration of Supplemental Oxygen by Day 2818.00 (13.00 to 27.00)17.00 (11.00 to 27.00)13.50 (10.00 to 21.00)
Statistical analysis
  • All Placebo vs MSTT1041A · Van Elteren · p = 0.5304 · Median difference (net): -1.00The median difference was calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Van Elteren · p = 0.5058 · Median difference (net): -4.50The median difference was calculated as the UTT1147A Arm minus the Placebo Arm.
SecondaryPercentage of Participants Alive and Free of Respiratory Failure by Day 28

Respiratory failure was defined as requiring non-invasive ventilation, high-flow oxygen, mechanical ventilation, or extracorporeal membrane oxygenation \[ECMO\]).

Time frame:
Up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Free of Respiratory Failure by Day 28
Percentage of participantsAll PlaceboMSTT1041AUTTR1147A
Percentage of Participants Alive and Free of Respiratory Failure by Day 2838.1 (29.47 to 46.65)39.2 (30.45 to 48.01)40.2 (31.41 to 48.89)
Statistical analysis
  • All Placebo vs MSTT1041A · Chi-squared · p = 0.8451 · Odds ratio (or): 1.05 · 95% CI 0.64 to 1.72The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Chi-squared · p = 0.7267 · Odds ratio (or): 1.09 · 95% CI 0.67 to 1.79The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Cochran-Mantel-Haenszel · p = 0.8458 · Odds ratio (or): 1.06 · 95% CI 0.63 to 1.79The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Cochran-Mantel-Haenszel · p = 0.7907 · Odds ratio (or): 1.08 · 95% CI 0.64 to 1.81The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryClinical Status Score at Day 14, Assessed Using a 7-Category Ordinal Scale

The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death

Time frame:
Day 14
Reported as:
Median · Score on a scale
Clinical Status Score at Day 14, Assessed Using a 7-Category Ordinal Scale
Score on a scaleAll PlaceboMSTT1041AUTTR1147A
Clinical Status Score at Day 14, Assessed Using a 7-Category Ordinal Scale1.0 (1.0 to 4.0)1.0 (1.0 to 3.0)1.0 (1.0 to 4.0)
Statistical analysis
  • All Placebo vs MSTT1041A · Van Elteren · p = 0.5273 · Median difference (final values): 0.0The median difference was calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Van Elteren · p = 0.6515 · Median difference (final values): 0.0The median difference was calculated as the UTT1147A Arm minus the Placebo Arm.
  • All Placebo vs MSTT1041A · Proportional Odds Model · p = 0.5475 · Odds ratio (or): 1.16 · 95% CI 0.71 to 1.91The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Proportional Odds Model · p = 0.5652 · Odds ratio (or): 1.16 · 95% CI 0.71 to 1.89The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryClinical Status Score at Day 28, Assessed Using a 7-Category Ordinal Scale

The clinical status scores of the 7 category ordinal scale are defined as follows: 1. Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or ≤2 Litres supplemental oxygen); 2. Non-Intensive Care Unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen; 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen; 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen; 5. ICU, requiring intubation and mechanical ventilation; 6. ICU, requiring ECMO or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy); 7. Death

Time frame:
Day 28
Reported as:
Median · Score on a scale
Clinical Status Score at Day 28, Assessed Using a 7-Category Ordinal Scale
Score on a scaleAll PlaceboMSTT1041AUTTR1147A
Clinical Status Score at Day 28, Assessed Using a 7-Category Ordinal Scale1.0 (1.0 to 4.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
Statistical analysis
  • All Placebo vs MSTT1041A · Van Elteren · p = 0.3401 · Median difference (final values): 0.0The median difference was calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Van Elteren · p = 0.4676 · Median difference (final values): 0.0The median difference was calculated as the UTT1147A Arm minus the Placebo Arm.
  • All Placebo vs MSTT1041A · Proportional Odds Model · p = 0.3408 · Odds ratio (or): 1.31 · 95% CI 0.75 to 2.29The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Proportional Odds Model · p = 0.3320 · Odds ratio (or): 1.32 · 95% CI 0.76 to 2.29The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryPercentage of Participants Needing Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Day 28
Time frame:
Up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Needing Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Day 28
Percentage of participantsAll PlaceboMSTT1041AUTTR1147A
Percentage of Participants Needing Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Day 2824.6 (16.96 to 32.29)28.5 (20.32 to 36.60)24.2 (16.55 to 31.93)
Statistical analysis
  • All Placebo vs MSTT1041A · Difference in percentage of participants: 3.83 · 95% CI -7.57 to 15.24The difference in percentage of participants was calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Difference in percentage of participants: -0.38 · 95% CI -11.46 to 10.70The difference in percentage of participants was calculated as the UTTR1147A Arm minus the Placebo Arm.
  • All Placebo vs MSTT1041A · Chi-squared · p = 0.4804 · Odds ratio (or): 1.22 · 95% CI 0.70 to 2.10The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Chi-squared · p = 0.9418 · Odds ratio (or): 0.98 · 95% CI 0.56 to 1.71The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Cochran-Mantel-Haenszel · p = 0.4988 · Odds ratio (or): 1.29 · 95% CI 0.68 to 2.44The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Cochran-Mantel-Haenszel · p = 0.9043 · Odds ratio (or): 1.02 · 95% CI 0.54 to 1.96The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryNumber of Ventilator-Free Days by Day 28

The number of ventilator-free days was defined as the number of days during the 28-day treatment period when the participant is alive and without need for invasive mechanical ventilation. For any day during Day 1 and Day 28, if invasive mechanical ventilation or ECMO was recorded for any part of the day ( \>= 12 hours during mechanical invasive ventilation for patients with tracheostomy), the day was not to be counted as a ventilator-free day; otherwise, the day was to be counted. For any days prior to Day 28 where status of mechanical ventilator was missing, the last known status was to be carried forward. The total number of days was the sum of all ventilator-free days, regardless of whether the days occurred consecutively or in nonconsecutive intervals.

Time frame:
Up to 28 days
Reported as:
Median · Days
Number of Ventilator-Free Days by Day 28
DaysAll PlaceboMSTT1041AUTTR1147A
Number of Ventilator-Free Days by Day 2828.0 (20.00 to 28.00)28.0 (20.00 to 28.00)28.0 (23.50 to 28.00)
Statistical analysis
  • All Placebo vs MSTT1041A · Van Elteren · p = 0.8007 · Median difference (net): 0.0Median difference was calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Van Elteren · p = 0.8633 · Median difference (net): 0.0Median difference was calculated as the UTTR1147A Arm minus the Placebo Arm.
SecondaryPercentage of Participants With an Intensive Care Unit (ICU) Stay by Day 28
Time frame:
Up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants With an Intensive Care Unit (ICU) Stay by Day 28
Percentage of participantsAll PlaceboMSTT1041AUTTR1147A
Percentage of Participants With an Intensive Care Unit (ICU) Stay by Day 2858.2 (49.48 to 66.93)54.6 (45.67 to 63.56)46.2 (37.33 to 55.10)
Statistical analysis
  • All Placebo vs MSTT1041A · Difference in percentage of participants: -3.59 · 95% CI -16.31 to 9.12The difference in percentage of participants was calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Difference in percentage of participants: -12.00 · 95% CI -24.67 to 0.67The difference in percentage of participants was calculated as the UTTR1147A Arm minus the Placebo Arm.
  • All Placebo vs MSTT1041A · Chi-squared · p = 0.5560 · Odds ratio (or): 0.86 · 95% CI 0.53 to 1.41The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Chi-squared · p = 0.0502 · Odds ratio (or): 0.62 · 95% CI 0.38 to 1.00The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Cochran-Mantel-Haenszel · p = 0.7002 · Odds ratio (or): 0.91 · 95% CI 0.51 to 1.60The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Cochran-Mantel-Haenszel · p = 0.0448 · Odds ratio (or): 0.57 · 95% CI 0.32 to 0.99The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryDuration of Intensive Care Unit (ICU) Stay by Day 28

Duration of ICU stay was calculated as the total number of hours (expressed in days) spent in ICU up to and inclusive of 28 days. ICU duration was derived from the ICU Stay Information Log using the difference between ICU discharge date/time and ICU admission date/time. If ICU admission occurred before randomization, the ICU duration was to be counted from the date of dosing. Partial admission and discharge date/time were to be imputed following a conservative approach. For each participant, durations of multiple ICU stays were to be summed.

Time frame:
Up to 28 days
Reported as:
Median · Days
Duration of Intensive Care Unit (ICU) Stay by Day 28
DaysAll PlaceboMSTT1041AUTTR1147A
Duration of Intensive Care Unit (ICU) Stay by Day 283.10 (0.00 to 5.23)2.62 (0.00 to 6.02)0.00 (0.00 to 2.14)
Statistical analysis
  • All Placebo vs MSTT1041A · Van Elteren · p = 0.4845 · Median difference (net): -0.48Median difference was calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Van Elteren · p = 0.0570 · Median difference (net): -3.10Median difference was calculated as the UTTR1147A Arm minus the Placebo Arm.
SecondaryTime to Clinical Failure by Day 28, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)
Time frame:
Up to 28 days
Reported as:
Median · Days
Time to Clinical Failure by Day 28, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)
DaysAll PlaceboMSTT1041AUTTR1147A
Time to Clinical Failure by Day 28, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)NA (13.0 to NA)NA (9.0 to NA)NA (NA to NA)
Statistical analysis
  • All Placebo vs MSTT1041A · Unstratified Log Rank · p = 0.4456 · Hazard ratio (hr): 1.19 · 95% CI 0.76 to 1.88The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Unstratified Log Rank · p = 0.7213 · Hazard ratio (hr): 0.92 · 95% CI 0.57 to 1.48The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Stratified Log Rank · p = 0.3963 · Hazard ratio (hr): 1.22 · 95% CI 0.77 to 1.96The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Stratified Log Rank · p = 0.9174 · Hazard ratio (hr): 0.97 · 95% CI 0.60 to 1.58The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryPercentage of Participants Who Died by Day 14
Time frame:
Up to Day 14
Reported as:
Number · Percentage of participants
Percentage of Participants Who Died by Day 14
Percentage of participantsAll PlaceboMSTT1041AUTTR1147A
Percentage of Participants Who Died by Day 146.0 (1.59 to 10.35)8.5 (3.29 to 13.63)8.3 (3.24 to 13.43)
Statistical analysis
  • All Placebo vs MSTT1041A · Difference in mortality rates: 2.49 · 95% CI -4.51 to 9.49The difference in mortality rates is calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Difference in mortality rates: 2.36 · 95% CI -4.58 to 9.31The difference in mortality rates is calculated as the UTTR1147A Arm minus the Placebo Arm.
  • All Placebo vs MSTT1041A · Chi-squared · p = 0.4336 · Odds ratio (or): 1.46 · 95% CI 0.57 to 3.74The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Chi-squared · p = 0.4543 · Odds ratio (or): 1.43 · 95% CI 0.56 to 3.68The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Cochran-Mantel-Haenszel · p = 0.4900 · Odds ratio (or): 1.46 · 95% CI 0.54 to 3.97The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Cochran-Mantel-Haenszel · p = 0.3595 · Odds ratio (or): 1.58 · 95% CI 0.58 to 4.28The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryPercentage of Participants Who Died by Day 28
Time frame:
Up to Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Who Died by Day 28
Percentage of participantsAll PlaceboMSTT1041AUTTR1147A
Percentage of Participants Who Died by Day 2811.2 (5.48 to 16.91)14.6 (8.16 to 21.07)12.9 (6.79 to 18.97)
Statistical analysis
  • All Placebo vs MSTT1041A · Difference in mortality rates: 3.42 · 95% CI -5.42 to 12.26The difference in mortality rates is calculated as the MSTT1041A Arm minus the Placebo Arm.
  • All Placebo vs UTTR1147A · Difference in mortality rates: 1.68 · 95% CI -6.89 to 10.26The difference in mortality rates is calculated as the UTTR1147A Arm minus the Placebo Arm.
  • All Placebo vs MSTT1041A · Chi-squared · p = 0.4067 · Odds ratio (or): 1.36 · 95% CI 0.66 to 2.80The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Chi-squared · p = 0.6728 · Odds ratio (or): 1.17 · 95% CI 0.56 to 2.46The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Cochran-Mantel-Haenszel · p = 0.5495 · Odds ratio (or): 1.33 · 95% CI 0.62 to 2.87The odds ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Cochran-Mantel-Haenszel · p = 0.5551 · Odds ratio (or): 1.24 · 95% CI 0.57 to 2.71The odds ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondaryTime to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) Aggregate Score of ≤2 Maintained for 24 Hours

The National Early Warning Score 2 (NEWS2) is a system for scoring the physiological measurements that are routinely recorded at the patient's bedside. Its purpose is to identify acutely ill patients. The NEWS2 scoring system measures 7 physiological parameters: respiration rate, peripheral capillary oxygen saturation, breathing air or supplementary oxygen, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, and body temperature. A score of 0, 1, 2, or 3 is allocated to each parameter (except for air or oxygen, with respective scores of 0 and 2); a higher score means the parameter is further from the normal range. The scores for each parameter are then summed (with an aggregate score ranging from 0 to 20), and a higher aggregate score indicates a worse clinical condition of the patient, thus indicating the need for a more urgent clinical response.

Time frame:
Up to 28 days
Reported as:
Median · Days
Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) Aggregate Score of ≤2 Maintained for 24 Hours
DaysAll PlaceboMSTT1041AUTTR1147A
Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) Aggregate Score of ≤2 Maintained for 24 Hours5.5 (4.0 to 7.0)6.0 (4.0 to 8.0)6.0 (3.0 to 9.0)
Statistical analysis
  • All Placebo vs MSTT1041A · Unstratified Log Rank · p = 0.3831 · Hazard ratio (hr): 1.31 · 95% CI 0.71 to 2.40The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Unstratified Log Rank · p = 0.5925 · Hazard ratio (hr): 1.18 · 95% CI 0.65 to 2.15The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
  • All Placebo vs MSTT1041A · Stratified Log Rank · p = 0.7487 · Hazard ratio (hr): 1.11 · 95% CI 0.60 to 2.05The hazard ratio was calculated as the MSTT1041A Arm relative to the Placebo Arm.
  • All Placebo vs UTTR1147A · Stratified Log Rank · p = 0.6092 · Hazard ratio (hr): 1.18 · 95% CI 0.63 to 2.21The hazard ratio was calculated as the UTTR1147A Arm relative to the Placebo Arm.
SecondarySafety Summary of the Number of Participants With at Least One Adverse Event, With Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

The terms "severe" and "serious" are not synonymous with respect to an adverse event (AE). Severity refers to the intensity of an AE (rated according to NCI-CTCAE v5.0 criteria or, if not listed, the following scale: Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death related to AE), whereas a serious AE (SAE) is a significant medical event (per standard SAE criteria), such as a life-threatening or fatal AE or an AE that prolongs inpatient hospitalization. Severity and seriousness were independently assessed by the investigator for each AE that was recorded. The investigator also assessed each AE for whether the event was considered to be related to the study drug.

Time frame:
From Baseline until study completion/discontinuation (up to 60 days)
Reported as:
Count of participants · Participants
Safety Summary of the Number of Participants With at Least One Adverse Event, With Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
ParticipantsAll PlaceboMSTT1041AUTTR1147A
Any Adverse Event (AE)878595
AE with Fatal Outcome232321
Serious AE (SAE)383834
SAE Leading to Withdrawal from Treatment221
SAE Leading to Dose Modification/Interruption000
Related SAE023
AE Leading to Withdrawal from Treatment433
AE Leading to Dose Modification/Interruption000
Related AE151225
Related AE Leading to Withdrawal from Treatment001
Related AE Leading to Dose Modification/Interruption000
Grade 3-5 AE434641
SecondaryNumber of Participants With Clinical Laboratory Test Abnormalities by Highest NCI-CTCAE Grade Post-Baseline

Clinical laboratory tests were performed over the course of the study and the grading of any abnormal values outside of the normal range (High or Low) was based on the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0); the higher the grade, the greater the lab parameter deviated from the normal range. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. SGPT/ALT = alanine aminotransferase; SGOT/AST = aspartate aminotransferase; INR = international normalized ratio; aPTT = activated partial thromboplastin time

Time frame:
From Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Test Abnormalities by Highest NCI-CTCAE Grade Post-Baseline
ParticipantsAll PlaceboMSTT1041AUTTR1147A
Albumin, Low - Any Grade103105118
Albumin, Low - Grade 1323640
Albumin, Low - Grade 2565866
Albumin, Low - Grade 3151112
Alkaline Phosphatase, High - Any Grade202324
Alkaline Phosphatase, High - Grade 1142222
Alkaline Phosphatase, High - Grade 2511
Alkaline Phosphatase, High - Grade 3101
SGPT/ALT, High - Any Grade604860
SGPT/ALT, High - Grade 1483747
SGPT/ALT, High - Grade 2577
SGPT/ALT, High - Grade 3535
SGPT/ALT, High - Grade 4211
SGOT/AST, High - Any Grade473844
SGOT/AST, High - Grade 1403036
SGOT/AST, High - Grade 2454
SGOT/AST, High - Grade 3022
SGOT/AST, High - Grade 4312
Calcium, Low - Any Grade738284
Calcium, Low - Grade 1344748
Calcium, Low - Grade 2312629
Calcium, Low - Grade 3574
Calcium, Low - Grade 4323
Calcium, High - Any Grade524
Calcium, High - Grade 1524
Creatinine, High - Any Grade243929
Creatinine, High - Grade 16118
Creatinine, High - Grade 2112415
Creatinine, High - Grade 3735
Creatinine, High - Grade 4011
Fibrinogen, Low - Any Grade731
Fibrinogen, Low - Grade 1110
Fibrinogen, Low - Grade 2320
Fibrinogen, Low - Grade 3200
Fibrinogen, Low - Grade 4101
Glucose, Low - Any Grade81112
Glucose, Low - Grade 1669
Glucose, Low - Grade 2150
Glucose, Low - Grade 3102
Glucose, Low - Grade 4001
Hemoglobin, Low - Any Grade777278
Hemoglobin, Low - Grade 1434746
Hemoglobin, Low - Grade 2171721
Hemoglobin, Low - Grade 317811
Hemoglobin, High - Any Grade975
Hemoglobin, High - Grade 1965
Hemoglobin, High - Grade 3010
Lymphocytes, Absolute Count (Abs), Low - Any Grade614548
Lymphocytes, Abs, Low - Grade 114911
Lymphocytes, Abs, Low - Grade 2231723
Lymphocytes, Abs, Low - Grade 3231811
Lymphocytes, Abs, Low - Grade 4113
Lymphocytes, Abs, High - Any Grade441
Lymphocytes, Abs, High - Grade 2441
Neutrophils, Total (Abs), Low - Any Grade531
Neutrophils, Total (Abs), Low - Grade 1430
Neutrophils, Total (Abs), Low - Grade 2101
Platelets, Low - Any Grade171712
Platelets, Low - Grade 114159
Platelets, Low - Grade 2202
Platelets, Low - Grade 3110
Platelets, Low - Grade 4011
Potassium, Low - Any Grade291925
Potassium, Low - Grade 2251823
Potassium, Low - Grade 3412
Potassium, High - Any Grade152516
Potassium, High - Grade 171912
Potassium, High - Grade 2533
Potassium, High - Grade 3231
Potassium, High - Grade 4100
INR, High - Any Grade716975
INR, High - Grade 1606167
INR, High - Grade 2986
INR, High - Grade 3202
aPTT, High - Any Grade474242
aPTT, High - Grade 1383536
aPTT, High - Grade 2653
aPTT, High - Grade 3323
Sodium, Low - Any Grade675858
Sodium, Low - Grade 1605051
Sodium, Low - Grade 2667
Sodium, Low - Grade 3110
Sodium, Low - Grade 4010
Sodium, High - Any Grade171623
Sodium, High - Grade 1111021
Sodium, High - Grade 2551
Sodium, High - Grade 3010
Sodium, High - Grade 4101
Bilirubin, High - Any Grade161411
Bilirubin, High - Grade 11298
Bilirubin, High - Grade 2252
Bilirubin, High - Grade 3201
Uric Acid, High - Any Grade332422
Uric Acid, High - Grade 3332422
Total Leukocyte Count, Low - Any Grade12610
Total Leukocyte Count, Low - Grade 110610
Total Leukocyte Count, Low - Grade 2200
SecondaryNumber of Participants With Vital Sign Abnormalities at Anytime Post-Baseline

The number of participants with vital sign abnormalities outside of the normal upper (i.e., High) and lower limits (i.e., Low) were summarized for each parameter. The normal reference range used for each vital sign parameter was as follows: Diastolic Blood Pressure, 50-90 millimetres of mercury (mmHg); Oxygen Saturation, ≥94%; Pulse Rate, 60-100 beats per minute; Respiratory Rate, 8-20 breaths per minute; Systolic Blood Pressure, 90-140 mmHg; Temperature, 36.5-38 degrees Celsius (C). Not every vital sign abnormality qualified as an adverse event. A vital sign result was to be reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment; resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgement.

Time frame:
From Baseline up to 60 days
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormalities at Anytime Post-Baseline
ParticipantsAll PlaceboMSTT1041AUTTR1147A
Diastolic Blood Pressure - Low232321
Diastolic Blood Pressure - High394339
Oxygen Saturation - Low112107105
Pulse Rate - Low666661
Pulse Rate - High756257
Respiratory Rate - Low102
Respiratory Rate - High108104103
Systolic Blood Pressure - Low201117
Systolic Blood Pressure - High778170
Temperature - Low116113113
Temperature - High131014
SecondaryNumber of Participants by the Investigator's Interpretations of Electrocardiogram Recordings at Specified Timepoints

Electrocardiogram (ECG) recordings were to be performed after the participant had been resting in a supine position for at least 10 minutes if possible. The investigator's interpretation of the ECG (e.g., normal or abnormal) was recorded.

Time frame:
Baseline, Days 14 and 28, Discharge Day (up to Day 28), and Study Completion Visit (up to Day 60)
Reported as:
Count of participants · Participants
Number of Participants by the Investigator's Interpretations of Electrocardiogram Recordings at Specified Timepoints
ParticipantsAll PlaceboMSTT1041AUTTR1147A
Baseline - Abnormal ECG566055
Baseline - Normal ECG766675
Day 14 - Abnormal ECG201314
Day 14 - Normal ECG141610
Day 28 - Abnormal ECG1234
Day 28 - Normal ECG323
Discharge Day - Abnormal ECG272837
Discharge Day - Normal ECG374739
Study Completion Visit - Abnormal ECG131821
Study Completion Visit - Normal ECG564640
Study Completion Visit - Unable to Evaluate ECG011
SecondaryPercentage of Participants Who Tested Positive for Anti-Drug Antibodies (ADAs) to MSTT1041A and UTTR1147A at Baseline and at Anytime Post-Baseline

Serum samples were collected, and participants who received treatment with MSTT1041A or MSTT1041A-matched placebo were assessed for antidrug antibodies (ADAs) to MSTT1041A, while those who received UTTR1147A or UTTR1147A-matched placebo were assessed for ADAs to UTTR1147A. Participants who received placebo treatment were only assessed for the presence of ADAs at baseline. The percentage of ADA-positive participants at baseline (baseline prevalence) and after drug administration (postbaseline incidence) are summarized. When determining postbaseline incidence, participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response).

Time frame:
At Baseline (pre-dose on Day 1) and post-baseline (Days 15 and 28; and discharge day and study completion [up to 60 days])
Reported as:
Number · Percentage of participants
Percentage of Participants Who Tested Positive for Anti-Drug Antibodies (ADAs) to MSTT1041A and UTTR1147A at Baseline and at Anytime Post-Baseline
Percentage of participantsMSTT1041A-Matched PlaceboMSTT1041AUTTR1147A-Matched PlaceboUTTR1147A
ADA Positive at Baseline3.42.61.71.6
ADA Positive Post-Baseline (Total)—2.9—0.9
Treatment-Induced ADA Positive Post-Baseline—1.9—0.9
Treatment-Enhanced ADA Positive Post-Baseline—1.0—0.0
SecondarySerum Concentration of UTTR1147A at Specified Timepoints
Time frame:
For the first dose: at 0.5 hours post-dose on Day 1, on Days 2, 3, 7, and 15; and for the second dose: Days 15 (0.5 hours post-dose), 21, and 28
Reported as:
Mean · nanograms per millilitre (ng/mL)
Serum Concentration of UTTR1147A at Specified Timepoints
nanograms per millilitre (ng/mL)UTTR1147A - PK Participants Who Only Received First DoseUTTR1147A - PK Participants Who Received Both DosesUTTR1147A - All PK Participants (First Dose Only or Both Doses), Days 1 to 15
Day 1, 0.5 hours post-dose1260 ± 5681600 ± 18201320 ± 952
Day 2707 ± 268674 ± 372700 ± 290
Day 3518 ± 221604 ± 222537 ± 223
Day 7258 ± 110259 ± 109258 ± 109
Day 15, pre-dose42.3 ± 27.888.1 ± 40.681.8 ± 41.9
Day 15, 0.5 hours post-dose—1410 ± 802—
Day 212.69 ± NA297 ± 147—
Day 2811.3 ± 8.89173 ± 78.4—
SecondarySerum Concentration of MSTT1041A at Specified Timepoints
Time frame:
For the first dose: at 0.5 hours post-dose on Day 1, on Days 2, 3, 7, and 15; and for the second dose: Days 15 (0.5 hours post-dose), 21, and 28
Reported as:
Mean · micrograms per millilitre (μg/mL)
Serum Concentration of MSTT1041A at Specified Timepoints
micrograms per millilitre (μg/mL)MSTT1041A - PK Participants Who Only Received First DoseMSTT1041A - PK Participants Who Received Both DosesMSTT1041A - All PK Participants (First Dose Only or Both Doses), Days 1 to 15
Day 1, 0.5 hours post-dose206 ± 71.1227 ± 66.7210 ± 70.4
Day 2175 ± 49.1178 ± 54.3176 ± 50.0
Day 3147 ± 40.1135 ± 41.0144 ± 40.4
Day 788.6 ± 32.383.9 ± 28.187.1 ± 30.9
Day 15, pre-dose32.2 ± 15.233.8 ± 17.233.5 ± 16.6
Day 15, 0.5 hours post-dose—144 ± 48.0—
Day 21—45.4 ± 20.8—
Day 28—22.5 ± 9.17—

Adverse events

Collected over From Baseline until study completion/discontinuation (up to 60 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Placebo23/134 (17.2%)38/134 (28.4%)29/134 (21.6%)
MSTT1041A23/130 (17.7%)38/130 (29.2%)42/130 (32.3%)
UTTR1147A21/132 (15.9%)34/132 (25.8%)40/132 (30.3%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventAll PlaceboMSTT1041AUTTR1147A
COVID-19 pneumoniaInfections and infestations5/1347/1305/132
Cardio-respiratory arrestCardiac disorders5/1340/1301/132
PneumothoraxRespiratory, thoracic and mediastinal disorders5/1342/1300/132
Respiratory failureRespiratory, thoracic and mediastinal disorders5/1344/1302/132
Septic shockInfections and infestations3/1343/1304/132
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1341/1304/132
Atrial fibrillationCardiac disorders2/1343/1300/132
COVID-19Infections and infestations2/1343/1301/132
PneumoniaInfections and infestations1/1343/1300/132
Acute kidney injuryRenal and urinary disorders2/1342/1303/132
Most frequent other events
Most frequent other events
EventAll PlaceboMSTT1041AUTTR1147A
ConstipationGastrointestinal disorders6/13410/13010/132
AnaemiaBlood and lymphatic system disorders6/1349/1307/132
HypokalaemiaMetabolism and nutrition disorders8/1349/1308/132
Dry skinSkin and subcutaneous tissue disorders5/1344/1309/132
HypertensionVascular disorders4/1348/1302/132
AnxietyPsychiatric disorders1/1345/1308/132
HeadacheNervous system disorders4/1347/1304/132
HypotensionVascular disorders5/1347/1305/132
NauseaGastrointestinal disorders2/1343/1307/132

Baseline characteristics

Modified Intent-to-Treat (mITT) Population: all participants randomized in the study who received at least one dose of study drug, with participants grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(Years)All PlaceboMSTT1041AUTTR1147ATotal
Mean56.0 ± 13.557.3 ± 13.457.8 ± 12.657.0 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)All PlaceboMSTT1041AUTTR1147ATotal
Female455652153
Male897480243
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All PlaceboMSTT1041AUTTR1147ATotal
Hispanic or Latino777270219
Not Hispanic or Latino535358164
Unknown or Not Reported45413
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All PlaceboMSTT1041AUTTR1147ATotal
American Indian or Alaska Native2406
Asian64515
Native Hawaiian or Other Pacific Islander0415
Black or African American1071027
White928789268
Unknown24242775
Region of Enrollment
Region of Enrollment(Participants)All PlaceboMSTT1041AUTTR1147ATotal
North America999797293
South America19202059
Western Europe16131544
Country of Enrollment
Country of Enrollment(Participants)All PlaceboMSTT1041AUTTR1147ATotal
Brazil19202059
Mexico14231754
Spain16131544
United States857480239
Mechanical Ventilation Required (Yes/No)
Mechanical Ventilation Required (Yes/No)(Participants)All PlaceboMSTT1041AUTTR1147ATotal
Yes, Baseline Mechanical Ventilation12131136
No Baseline Mechanical Ventilation122117121360
Clinical Status Score at Baseline
Clinical Status Score at Baseline(Participants)All PlaceboMSTT1041AUTTR1147ATotal
Clinical Status Score of 10000
Clinical Status Score of 23418
Clinical Status Score of 3474957153
Clinical Status Score of 4716463198
Clinical Status Score of 5108826
Clinical Status Score of 63429
Clinical Status Score of 70000
Clinical Status Score Not Available0112
08

Study locations

41 sites
  • University of Arkansas For Medical Sciences
    Little Rock, Arkansas 72205, United States
  • eStudySite - Chula Vista - PPDS
    Chula Vista, California 91911, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Torrance Memorial Medical Center
    Torrance, California 90505, United States
  • Denver Health Medical Center
    Denver, Colorado 80204, United States
  • Bay Pines VA Medical Center - NAVREF
    Bay Pines, Florida 33744, United States
  • WellStar Research Institute
    Marietta, Georgia 30060, United States
  • DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS
    Alexandria, Louisiana 71301, United States
  • MedPharmics
    Metairie, Louisiana 70006, United States
  • Southeast Louisiana Veterans Health Care System - NAVREF
    New Orleans, Louisiana 70112, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • St. Joseph'S Regional Medical Center
    Paterson, New Jersey 07503, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Lincoln Medical Mental Health Center
    Bronx, New York 10451, United States
  • Staten Island University Hospital; Department of Pharmacy
    Staten Island, New York 10305, United States
  • Mercy St. Vincent Medical Center
    Toledo, Ohio 43608, United States
  • Providence Portland Medical Center; Investigational Drug Services/Regional Research
    Portland, Oregon 97213, United States
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18103, United States
  • Parkland Health & Hospital System
    Dallas, Texas 75235, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23292, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility
    Tacoma, Washington 98405, United States
  • Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ
    Rio de Janeiro, RJ 21040-360, Brazil
  • Santa Casa de Porto Alegre
    Porto Alegre, RS 90020-090, Brazil
  • Hospital E Maternidade Celso Pierro PUCCAMP
    Campinas, SP 13060-904, Brazil
  • Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto
    Sao Jose Do Rio Preto, SP 15090-000, Brazil
  • Hospital Alemao Oswaldo Cruz
    Sao Paulo, SP 01323-903, Brazil
  • Instituto do Coração - HCFMUSP
    Sao Paulo, SP 05403-900, Brazil
  • Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca
    Guadalajara, Jalisco 44340, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo LEON, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Mexico, Mexico
  • Instituto Nacional De Enfermedades Respiratorias INER National Institute of Respiratory Diseases
    Mexico, Mexico
  • Hospital General de Tijuana
    Tijuana, 22320, Mexico
  • Hospital Universitario de Bellvitge
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Costa del Sol; Servicio de Oncologia
    Marbella, Malaga 29603, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital General Universitario de Guadalajara
    Guadalajara, 19002, Spain
  • Complejo Asistencial Universitario de Salamanca - H. Clinico
    Salamanca, 37007, Spain
  • Hospital Clinico Universitario Valladolid
    Valladolid, 47005, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jan 2021, 7 months.

Results were first posted in Jan 2022, 1 year after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 7 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2020
First posted
May 13, 2020
StartActual
Jun 2, 2020
Primary completionActual
Jan 8, 2021
CompletionActual
Feb 12, 2021
Results first posted
Jan 10, 2022
Last update
Jan 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04386616
Lead sponsor
Genentech, Inc.
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
May 13, 2020
Start date
Jun 2, 2020
Primary completion
Jan 8, 2021
Completion
Feb 12, 2021
Results posted
Jan 10, 2022
Last update
Jan 10, 2022

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Astegolimab · Efmarodocokin alfa

Start the discussion